Skip to content
value.today
Atossa Genetics logo

Atossa Genetics

ATOS
$26 Mmarket cap on Oct 14, 2026-78.0% since Jan 2024
Compare
World rank
#23,585
Revenue
—
For year ending December-2025
Net income
$-35 M
SEC filing
Employees
—

Atossa Genetics in brief

Atossa Genetics is a listed company in the Biotechnology industry, based in Seattle, Washington, USA. Its market value was $26 M on 14 October 2026, which makes it the 23,585th largest listed company in the world and the 4,083rd largest in the USA on this site. Steven C. Quay is its chief executive. Its shares trade under the symbol ATOS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Atossa Genetics timeline

3 events, 2010–2019
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2012
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2019
  6. ✎
    Renamed Atossa Therapeutics, Inc.
    Formerly Atossa Genetics Inc.

Events of Atossa Genetics from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$52 M$105 M$157 M$210 M2020202120222023202420252026

World rank over time

▲ up 2,042 places since 2020
2020-01-01: #25672#25,67220202021-01-01: #21207#21,20720212022-01-07: #19181#19,18120222022-12-25: #23267#23,26720222023-07-30: #19906#19,90620232024-01-05: #20694#20,69420242026-03-08: #11270#11,27020262026-08-01: #21173#21,17320262026-10-14: #23630#23,6302026

Rank in USA: #4,559 (Jan 2020) · #4,146 (Jan 2021) · #3,862 (Jan 2022) · #4,515 (Dec 2022) · #3,905 (Jul 2023) · #3,599 (Jan 2024) · #2,195 (Mar 2026) · #3,891 (Aug 2026) · #4,058 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.6×
Free cash flow yield
-116.6%
Net margin
—
Operating margin
—
Return on equity
-88.4%
Liabilities / assets
17.3%
Net debt
$-8M
Revenue growth
+31.3%
R&D / revenue
176.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-11M—FY18Fiscal year ending Dec 2019: revenue —, net income $-17M—FY19Fiscal year ending Dec 2020: revenue —, net income $-18M—FY20Fiscal year ending Dec 2021: revenue —, net income $-21M—FY21Fiscal year ending Dec 2022: revenue —, net income $-27M—FY22Fiscal year ending Dec 2023: revenue —, net income $-30M—FY23Fiscal year ending Dec 2024: revenue —, net income $-26M—FY24Fiscal year ending Dec 2025: revenue —, net income $-35M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-37M$-35M—
Dec 2024——$-28M$-26M—
Dec 2023——$-31M$-30M—
Dec 2022——$-28M$-27M—
Dec 2021——$-21M$-21M—
Dec 2020——$-15M$-18M—
Dec 2019——$-17M$-17M—
Dec 2018——$-11M$-11M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-30M$0M$-30M$-4.04—
Dec 2024$-21M$0M$-21M$-3.04—
Dec 2023$-21M$0M$-21M$-0.24—
Dec 2022$-21M$0M$-21M$-0.21—
Dec 2021$-16M$0M$-16M$-0.18—
Dec 2020$-12M$0M$-12M$-1.97—
Dec 2019$-9M$0M$-9M$-2.03—
Dec 2018$-9M$0M$-9M$-5.50—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-6M—Dec ’24Three months to Mar 2025: revenue —, net income $-7M—Mar ’25Three months to Jun 2025: revenue —, net income $-8M—Jun ’25Three months to Sep 2025: revenue —, net income $-9M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-11M—Dec ’25Three months to Mar 2026: revenue —, net income $-10M—Mar ’26Three months to Jun 2026: revenue —, net income $-8M—Jun ’26Three months to Sep 2026: revenue —, net income $-6M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Atossa Genetics with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-37 M
Net income
$-35 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$48 M
Total liabilities
$8 M
Total equity
$39 M

As of December-2025

Top 35 institutional investors in Atossa Genetics#

As of Sep 30, 2026
35 institutions held 971,077 shares (about 9.7% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.3%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Atossa Genetics
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC361,7470 (0.00%)3.63%$1 MNov 13, 2026
2BlackRock, Inc.168,621+4,263 (+2.59%)1.69%$0 MNov 13, 2026
3Renaissance Technologies LLC109,907-22,136 (-16.76%)1.10%$0 MNov 12, 2026
4Geode Capital Management, LLC95,577+3,195 (+3.46%)0.96%$0 MNov 6, 2026
5Vanguard Fiduciary Trust Co52,5830 (0.00%)0.53%$0 MNov 13, 2026
6State Street Corp39,7610 (0.00%)0.40%$0 MNov 12, 2026
7UBS Group AG30,508-52,112 (-63.07%)0.31%$0 MNov 10, 2026
8Ameriprise Financial Inc27,412-230,822 (-89.38%)0.27%$0 MNov 16, 2026
9Susquehanna International Group, LLP21,513+5,939 (+38.13%)0.22%$0 MNov 16, 2026
10Northern Trust Corp20,213-36 (-0.18%)0.20%$0 MNov 16, 2026
11Millennium Management LLC14,867-31,641 (-68.03%)0.15%$0 MNov 16, 2026
12Morgan Stanley12,3450 (0.00%)0.12%$0 MNov 13, 2026
13Royal Bank Of Canada4,885+2,891 (+144.98%)0.05%$0 MNov 16, 2026
14Vanguard Global Advisers, LLC3,0890 (0.00%)0.03%$0 MNov 13, 2026
15Barclays PLC2,558New0.03%$0 MNov 6, 2026
16Jones Financial Companies Lllp2,0610 (0.00%)0.02%$0 MNov 13, 2026
17NewEdge Advisors, LLC1,127New0.01%$0 MNov 13, 2026
18Osaic Holdings, Inc.5870 (0.00%)0.01%$0 MNov 12, 2026
19Rockefeller Capital Management L.P.3330 (0.00%)0.00%$0 MNov 13, 2026
20Rydar Equities, Inc.333New0.00%$0 MOct 13, 2026
21Harbour Investments, Inc.176+66 (+60.00%)0.00%$0 MNov 9, 2026
22SBI Securities Co., Ltd.1480 (0.00%)0.00%$0 MOct 22, 2026
23Wells Fargo & Company/mn145-83 (-36.40%)0.00%$0 MNov 16, 2026
24BFC Planning, Inc.124New0.00%$0 MNov 13, 2026
25TD Waterhouse Canada Inc.1030 (0.00%)0.00%$0 MOct 16, 2026
Show all 35: investors 26 to 35
Institutional investors 26 to 35 in Atossa Genetics
#InstitutionShares heldChange (shares)% heldValueFiled
26BNP Paribas Financial Markets870 (0.00%)0.00%$0 MNov 12, 2026
27NBH Bank69New0.00%$0 MNov 5, 2026
28Allworth Financial LP66New0.00%$0 MNov 17, 2026
29Bolton Securities Corporation500 (0.00%)0.00%$0 MNov 12, 2026
30FMR LLC35New0.00%$0 MNov 10, 2026
31IFP Advisors, Inc29New0.00%$0 MOct 16, 2026
32Caitong International Asset Management Co., Ltd8+2 (+33.33%)0.00%$0 MOct 29, 2026
33Bogart Wealth, LLC50 (0.00%)0.00%$0 MNov 10, 2026
34Clearstead Advisors, LLC40 (0.00%)0.00%$0 MNov 6, 2026
35Citigroup Inc1New0.00%$0 MNov 4, 2026

Mutual funds holding Atossa Genetics#

12 funds hold shares worth $2 M (about 7.1% of the company). Since their previous reports 5 added shares and 4 sold, buying $0 M net.
Mutual funds holding Atossa Genetics
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.256,137$0 M2.6%<0.01%no changeJun 30, 2026
🇺🇸 Columbia Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC201,434$0 M2.0%0.02%+6.4%Jul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC46,409$0 M0.47%<0.01%−0.8%May 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.99,071$0 M0.99%<0.01%+15%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC14,382$0 M0.14%<0.01%no changeMay 31, 2026
🇺🇸 Columbia Variable Portfolio - Small Cap Value Discovery FundColumbia Management Investment Advisers, LLC36,383$0 M0.36%0.02%−4.0%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC12,643$0 M0.13%<0.01%+13%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors29,203$0 M0.29%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC4,211$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.6,539$0 M0.07%<0.01%no changeJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,986$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors952$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 12 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Atossa Genetics#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
11
since
$44 K-$33 K$0Nov 2023: bought $0 (0 trades), sold $33 K (1 trades)Nov 23Apr 2024: bought $44 K (1 trades), sold $0 (0 trades)AprMar 2025: bought $7 K (1 trades), sold $0 (0 trades)MarMay 2025: bought $10 K (1 trades), sold $0 (0 trades)May
Bought (open market)Sold (open market)Hover a month for the totals
Atossa Genetics: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jonathan FinnDirectorGrant or award+10,000——11,666Form 4
filed Shu-Chih ChenDirectorGrant or award+10,000——10,000Form 4
filed H. Lawrence RemmelDirectorGrant or award+10,000——10,683Form 4
filed Tessa CiglerDirectorGrant or award+10,000——10,000Form 4
filed Stephen J. GalliDirectorGrant or award+10,000——10,006Form 4
filed Richard I. SteinhartDirectorGrant or award+10,000——10,000Form 4
filed Steven C. QuayPresident & CEO, DirectorGrant or award+65,000——88,038Form 4
filed Mark James DanielChief Financial OfficerGrant or award+63,000——63,000Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Atossa Genetics#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
526,812
7.59 days to cover
Buybacks, Q4 2023
$0M
Q4 2023
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-14.93 reverse split

Atossa Genetics share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2023Q4 2023$0M
Q4 2022Q4 2023$0M

Trading halts

  • 2026-01-31 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 165 shares at $2.56
  • : 31 shares at $2.39
  • : 687 shares at $2.45
  • : 1 shares at $2.34
  • : 1,708 shares at $2.05

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Atossa Genetics scorecard#

Passes 2 of the 12 checks that could be worked out: strongest in valuation (1 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 14, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-116.6%Free cash flow is -116.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.04 vs -3.04Diluted EPS -4.04 in fiscal 2025 against -3.04 the year before (report's currency).
    • ✗Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$18 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-62.7%-62.7% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities5.5×Current ratio 5.52 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.6%Diluted shares up 2.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Atossa Genetics: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Atossa Genetics: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development211417159.26.6r6.64.22.30.8
General and administrative16141413118.0117.24.96.5
Operating expenses372831282115r17117.68.0
Operating income−37−28−31−28−21−15r−17−11−7.6−8.0
Interest and finance income2.44.14.30.90.0—————
Other non-operating income (expense)−0.0−0.2−0.1−0.1−0.1r0.1r0.00.00.01.6
Income before tax−35−26−30−27−21−18r−17−11−8.1−6.4
Income tax000000000—
Income from continuing operations—————————−6.4
Net income attributable to shareholders−35−26−30−27−21−18r−17−11−8.1−6.4
Earnings per share, basic-4.04-3.04r-0.24-0.21-0.18-1.97-2.03-5.50-10.97r-2.16r
Earnings per share, diluted-4.04-3.04r-0.24-0.21-0.18-1.97-2.03-5.50-10.97r-2.16r
Shares, weighted average (basic)8.68.4r126127r117—————
Shares, weighted average (diluted)8.68.4r1261270.10.0r8.54.21.0r2.9r
Balance sheet
Cash and cash equivalents41718811113640r13107.23.0
Other current assets1.11.22.22.41.20.7r0.00.00.0—
Current assets46749211814143r14127.93.3
Property, plant and equipment————0.00.0r0.00.10.00.1
Right-of-use (leased) assets———000.0r0.1———
Other intangible assets————0.10.0r0.2r0.2r0.2r0.6
Total assets48769612414143r14128.24.1
Accounts payable4.30.70.83.01.71.6r0.30.40.30.3
Current liabilities8.35.05.25.63.116r1.32.91.21.0
Lease liabilities (non-current)——————0.0———
Total liabilities8.35.05.25.63.116r1.32.9—1.0
Retained earnings−247−212−186−156−129−112r−94−77−65−57
Shareholders' equity39719111813827r13r8.86.93.1
Total liabilities and equity48769612414143r14128.24.1
Shares outstanding8.68.6r125127r12748r9.15.82.7r3.8
Cash-flow statement
Depreciation and amortization———0.00.00.0r0.10.00.10.3
Share-based compensation2.62.34.66.85.33.0r7.1r1.10.80.9
Cash from operating activities−30−21−21−21−16−12r−9.1−9.0−6.6−5.4
Capital expenditure−0.0−0.0−0.0−0.0−0.0−0.0r−0.0−0.1——
Cash from investing activities−0.0−0.0−0.0−4.7−0.0−0.0r−0.0−0.1—−0.0
Shares issued————————6.24.7
Shares bought back—0−1.50——————
Cash from financing activities03.7−1.5011339r1112114.7
Change in cash−30−17−22−259727r2.23.24.2−0.7
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Atossa Genetics#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.5 M
Dr. Quay
Other top executives, average
$759 K
the CEO earned 3.3× this
$100 invested is now
—
Atossa Genetics: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Quay$2.5 M$2.2 M$759 K—
2024Dr. Quay$2.8 M$3.0 M$1.1 M$79
2023Dr. Quay$2.4 M$2.7 M$1.4 M—

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Atossa Genetics#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Directors and officers 1 · Material agreement 3 · Agreement ended 1 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 7

Atossa Genetics: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementShareholder rights changed8-K
Results announced8-K
Material agreement8-K
Shareholder vote8-K
Material agreementAgreement ended8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Atossa Genetics
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2013$1 MPrivate placement after listingUnder $2 million1equitySEC
Apr 2011$7 MNo. 1$2 to $10 million156equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Atossa Genetics#

$40 K spent on lobbying the US Congress and federal agencies in 2021, most often on medical/disease research/clinical labs.

Lobbying, 2021
$40 K
#1,268 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2021
2026 so far
—
  • Medical/Disease Research/Clinical Labs1 report

Lobbying firms hired in 2021

Desimone Consulting, LLC $40 K

Atossa Genetics: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$40 K—1
2020$100 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Atossa Therapeutics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Atossa Genetics compares in Biotechnology

  • Market cap$26 M · higher than 20% of 726
  • Revenue growth31.3% · higher than 67% of 438
  • Price / book0.7× · lower than 87% of 534
  • FCF yield-116.6% · higher than 9% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Atossa Genetics🇺🇸$26 M——+31.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 14, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Atossa Genetics? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Atossa Genetics's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Atossa Genetics? Suggest a correction